BPC-157 Cannabis Interaction Profile: What the Evidence Actually Shows

What is known about taking BPC-157 with cannabis?

BPC-157 is a synthetic 15-amino-acid peptide sold as capsules, injections, oral sprays and nasal sprays, some labeled for research use only [1]. It is not an FDA-approved drug, and FDA's 2026 review found no approved product containing it in any country it searched [1]. So there is no FDA-approved label with an interaction section for BPC-157 [1].

The direct answer is short: FDA's review of the human studies of BPC-157 describes no study that gave it with cannabis, THC or CBD [1]. There is also no human pharmacokinetic data for BPC-157 by the oral, subcutaneous, nasal or skin routes [1]. After rectal enemas in two early studies, BPC-157 was mostly not detectable in blood, and FDA judged it appears not to be absorbed systemically by that route [1].

Do BPC-157 and cannabis share measurable pathways?

Only in separate observations, not in a tested combination. FDA says BPC-157's molecular targets have not been identified and its mechanisms remain poorly understood [1]. Animal work reports effects on nitric oxide, dopamine and serotonin systems [6][7]. One rat study found BPC-157 changed the effects of a nitric-oxide inhibitor on stomach lesions and blood pressure, and had no effect on normal resting blood pressure [7]. That study did not test cannabis. Rat work also reports gut lesion healing [5].

Cannabis has its own measured effects. Acute THC increases dopamine release and neuron activity, while long-term use is associated with blunting of the dopamine system [2]. Cannabis overdose can increase heart rate and change blood pressure [3]. The endocannabinoid system is an important regulator of gastrointestinal motility [4].

Those facts do not add up to an interaction profile. No study cited here measured BPC-157 and THC or CBD together, and the human effects of BPC-157 that would matter, such as changes in blood pressure, gut transit or dopamine tone, are not established.

What human evidence exists for BPC-157?

The human evidence is small and weak. A 2026 systematic review found 3 studies with 30 patients total, all of poor methodological quality, with certainty of evidence rated very low [8]. FDA found five small clinical studies, including a 2-person intravenous pilot, and concluded there is insufficient clinical safety information to characterize BPC-157's safety profile [1].

FDA's adverse-event database search through December 4, 2025 found 3 reports, all injectable BPC-157: injection-site redness and swelling for 9 days, shortness of breath leading to an emergency room visit, and widespread skin and gum darkening that recurred on re-exposure to a BPC-157 plus TB-500 product [1]. FDA said it cannot tell whether BPC-157 caused these events [1].

Animal toxicity signals include shortened clotting time in rats and prolonged clotting time in dogs in 28-day intramuscular studies, plus raised liver enzyme, glucose and triglyceride levels [1]. It is unknown whether cannabis changes any of those signals.

What is BPC-157's regulatory status?

BPC-157 is not FDA-approved and has no US Pharmacopeia or National Formulary monograph [1]. FDA placed it in category 2 for significant safety risks from September 2023 until April 22, 2026, then moved it to a nominated-but-withdrawn table after the nominators withdrew; it is not in category 1 [9][10]. A 2026 HHS draft enforcement-discretion policy for certain peptides is not an approval and does not put BPC-157 on FDA's pharmacy bulks list [11]. It is a non-binding statement that HHS does not intend to take enforcement action against certain state-licensed pharmacies and physicians if conditions are met [11].